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Half-Life Time and Control Frequency of
Vitamin K-Dependent Coagulation Factors
Theoretical Considerations on the Place of Factor VII in the Control of
Oral Anticoagulation Therapy
M.C.E. van Dam-Mieras, H.C. Hemker
Department of Biochemistry, Limburg University, Maastricht, The Netherlands
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Abstract. A short review about the place of coagulation factor VII in the initial phase of
blood coagulation is given. A theoretical model describing the relationship between the half-
life times of vitamin K-dependent coagulation factors and the control frequency of oral anti-
coagulation therapy is presented. The constraints that control frequency imposes on the type
of determination to be carried out are discussed.
Introduction
It is well known from the literature that
part ofthe coagulation cascade reactions pro-
ceed at lipid/water interfaces. The enzymes
and substrates in these surface-mediated
reactions are the vitamin K-dependent coag-
ulation factors. It is possible to regulate the
efficiency of the heterogeneous catalysis
through manipulation of the aflinity for lip-
id/water interfaces of the coagulation factors
involved. Oral anticoagulation is based on
this principle. Today, oral anticoagulation
therapy is usually controlled by a general
analytical method sensitive to the overall ef-
fect on several of the vitamin K-dependent
coagulation factors (VII, IX, X and II). The
advent of automatable amidolytic tests mea-
suring the different vitamin K-dependent
factors independently actualizes the discus-
sion on the relative importance of single vita-
min K-dependent factors in the control of
oral anticoagulation therapy. This discussion
in the older literature mostly goes in the form
of debates on the importance of 'factor X
sensitivity' of thromboplastins. The hard
facts on which one can decide what factors
are important in this respect are: (1) The bio-
logical half-life times of the vitamin K-de-
pendent coagulation factors. (2) The levels of
the vitamin K-dependent coagulation factors
that are acceptable to ensure adequate anti-
coagulation (upper limit) and to prevent
bleeding (lower limit).
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Whereas point I is well known lvan der
Meer et al., 1968], no hard data are avail-
able on point 2; it is not known, for exam-
ple, whether 2.5o/o f factor VII will cause a
serious bleeding tendency or not. In other
words it is not easily predicted how a factor
VII level as low as 2.5o/o will be expressed
in the overall coagulation capacity ofblood,
or whether a level of 300/o of factor IX
will carry a significant risk of thrombo-
sis.
Although the discussion on what level of
which individual factor is acceptable has not
been carried to a conclusion, in practice the
decision for all practical purposes has already
been made on the moment that the frequency
of the control of oral anticoagulant therapy
has been decided, because there is a relation-
ship between the control frequency and the
half-life time of the coagulation factors ac-
tually followed in an overall test. Qualita-
tively this will be easily understood. It is no
use to control factor II levels daily if the
response of the factor II level to changes in
dosage of oral anticoagulants is limited by the
fact that its biological half-life time is 2t/z
days. On the other hand it does not seem use-
ful either to choose a parameter with a bio-
logical half-life of a few hours when the con-
trol frequency is only one control per 6
weeks. The situation is akin to the registra-
tion of electric phenomena on a strip-chart
recorder. If the dampening of the instrument
is too high, fast signals will be missed, if it is
too low, too much noise will be recorded. We
present in this article a theoretical model
meant to explore the relation between the
half-life times of the factors to be measured
and the control frequency. We also discuss
the constraints that control frequency im-
poses on the type of determination to be car-
ried out.
Special Position of Factor VII among the
Vitamin K-Dependent Coagulation
Factors
Recent research in the coagulation field
has shown that the familiar picture of an
intrinsic and extrinsic pathway of coagula-
tion joining at the factor X activation step is
far too simple. There exist close connections
between the initiating reactions of both path-
ways [see also the contribution of Prydz in
this issuel.
In the 'classical' concept factor VII is acti-
vated upon interaction with tissue thrombo-
plastin and the intrinsic pathway is triggered
by the exposure of blood to negatively
charged surfaces. Several authors have shown
that factor XII. and Hageman factor frag-
ments activate bovine factor VII lAltman
and Hemker, 1967; Kisiel et al., 1977; Rad-
clffi et al., 19771. Seligsohn et al. [978,
l9l9a, b] showed in a human system that
both XII. and IXu activate factor VII. These
authors state that after surface contact, XII"
is the principal activator of factor VII and
after clotting, IXu is the principal factor VII
activator. Kallikrein acts indirectly by acti-
vating factors XII and XI. Morrison-Silver-
berg and Jesty ll98ll using a bovine system
argued that a ternary complex of tissue fac-
tor, factor VII and factor Xu would be the
form of factor VII responsible for a further
generation of factor IX" and factor Xu during
the period preceding clot formation. Only
0.20lo f the total plasmatic content of factor
X needs to be activated to give a maximal
expression of VII activity and the generation
of activity in the system could be extremely
rapid because it would only depend upon the
formation of a Michaelis-type complex and
not upon a proteolytic splitting. Radclffi and
Nemersonl l975,1976l have shown that in a
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purified system first there is a rapid acliva-
tion followed by a slower inactivation of fac-
tor VII by factor Xu. In whole plasma, where
inhibitors of factor X" are also present, an
inactivation of factor VII" by factor Xu is not
so easily proyen, but it is not unlikely that
also here factor X" might exert a negative
control function. Furthermore, thrombin and
plasmin can also enhance factor VII activity
lZur and Nemerson, 1980; Osterud et al.,
l  9801.
On the other hand, both in human and
bovine systems factors IX and X can be acti-
vated by the tissue factor-Vllu complex
lJosso and Prou-Wartelle, 1965; Osterud and
Rapaport, 1977, 1980; Jesty and Silverberg,
19791. It has been shown that factors IX and
X are competitive inhibitors with regard to
their respective activation by the tissue fac-
tor-VIIu complex. When the activation of
factors IX and X was studied in a system
mimicking bovine plasmatic conditions
lJerty and Silverberg, l979lX activation pro-
ceeded about 7 times faster than IX activa-
tion. Using human reagents, Osterud and Ra-
paport [1980] reported that the two activa-
tion rates were equal.
Finally there are clinical indications
pointing to the close connection between in-
trinsic and extrinsic pathways. Usually, pa-
tients with very low levels of factor XII or
factor XI do not show a bleeding tendency
while the hemorrhagic problems in factor
VIII- and factor IX-deficient patients are well
known. Aiyappa [981a, b] described a chro-
mogenic analogue of the APTT test that
turned out to be sensitive not only to defi-
ciency of the factors XII, prekallikrein, XI,
IX, VIII, V, X and II but to factor VII deh-
ciency as well. Bertina et al. [981] described
a patient with an abnormal factor X mole-
cule: it is normallv activated bv the factors
IX", IX.+VIII and RW-X but only very
slowly by the thromboplastin factor VII com-
plex. This patient never showed bleeding
complications.
The short review given above [see also the
article of Prydz in this issuel clearly shows
that the extrinsic and intrinsic pathways of
the coagulation cascade are intimately linked.
Many experiments will be needed to com-
pletely elucidate this complicated system.
However, one thing emerges very clearly: fac-
tor VII must play a central and important
role in the initial phase of blood coagulation.
This idea is further supported by the factthat
contrary to the other vitamin K-dependent
coagulation factor zymogens, factor VII has
relatively strong esterase activity in its native
(one-chain) form fZaugg, 1980; Zur and Ne-
merson, 1980; Radclffi and Nemerson,
19751. Finally the in vitro occurrence ofcold-
promoted activation, the fact that factor VII.
in plasma stored at 4 " C is stable for several
days [Seftgsohn et al., 1978a, b], the persis-
tence of activated factor VII in circulation for
several hours (tYz = 144 min) after transfu-
sion of factor IX concentrates lSeligsohn et
al.,1979a, bl and the observation that anti-
thrombin III does not inactivate factor VII"
losterud et al., 1976; Jesty, 19781all point to
the special place factor VII takes among the
serine esterase enzymes of the coagulation
cascade.
Factor VII might be an important factor
in the control of bleeding and thrombotic
tendencies. Clinical assays of factor VII and
its activity state in plasma could be of great
diagnostic importance lHemker et al., 1976;,
Poller et al., 1981; Avvisati et al., 1980; Selig-
sohn etal.,1978b; Aiyappa, 1981a, bl. On the
basis of these observations the importance of
measuring factor VII theoretically may be
sustained. On the other hand, having in mind
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the relatively short half-time value of factor
YIIfvan der Meer et al., 1968] one may ask if
a factor VII assay is suitable for the control of
oral anticoagulation therapy when the con-
trol frequency in practice varies between
once per day and once per 6 weeks.
Theoretical Model
In the following a theoretical model is pre-
sented which gives a relation between the
biological half-life times of vitamin K-depen-
dent coagulation factors and the control fre-
quency of anticoagulation therapy. In the
construction of the model it is assumed that
the coagulation factor levels approach the
level eventually dictated by the rate of syn-
thesis in the liver by first-order kinetics and
that the processes leading to increase respec-
tively decrease of these levels are character-
ized by the same kinetic parameters lvan der
Meer et al., 19681. Figure I shows a practical
situation. At a given time t = 0, the level of a
given vitamin K-dependent coagulation fac-
tor is o and t units of time, later the level of
the same factor is p. It is not likely that dur-
ing the time lapse t the coagulation factor
level follows the straight line u-B; it will
sometimes lie above and sometimes beneath
this line. The lowest value that can be
reached between two controls o and B is
found when the level decreases after point o
and then again increases to reach level p. This
situation is represented by the line a -n-i,-B
in figure 2.
The curves o-rmin and n6rr-B can be de-
scribed by first-order kinetics (see above):
16i,  = f l ,  g-ktmin ( l )
and 100 - P = (100-nmii s-k(t-t.il (2)
Substitution of equation 1 in equation 2
gives:
1 0 0 - B  
. n m i n _ e _ k t
1 0 0 - n - 6  o
which, because of the first-order character,
can be rewritten as:
l9O-B .n^tn=1yr7rr,  (3)
100 -  n- in 0
For reasons of simplicity of the calcula-
tions to follow a new variable q is intro-
duced:
l/ o = (lz)!tn,
rearrangement of equation 3 then gives:
r00 (4)flmin =
'(Y).'
Equation 4 is used to calculate table I
starting from the situation of stable anticoa-
gulation (o = F).
From table I it follows that when a vita-
min K-dependent coagulation factor level of
20o/o is maintained in 'stable anticoagula-
tion', dangerously low values (< 5 o/o) can be
reached within 3 half-time values if sudden
overdosage causes blocking of the coagula-
tion factor synthesis.
Exactly the same reasoning can be fol-
lowed to find the value nmax between the
points c and p (cf. frg. 2); for the curve o-nmax
we can write:
100-n*"* = (100 - o) e-kt.". (5)
and for the descending limb of the curve
0 = II-* e-k(t-tnal (6)
Combination of equations 5 and 6 gives
100-n-- .  F *  
"_no r1.",
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100 "/"
Time.*
Fig. 1. Time course ofthe coagu-
lation factor level between two suc-
cessive controls. At the time t = 0 a
level o is measured: t units of time
later the level is p.
Fig.2. Representation of the
theoretically calculated maximal
(n-) and minimal (n.s) values the
coagulation factor level can reach
between two successive controls (o
and 9).
Table I. nmin values as a function of o, B and (Vty)
v rVD
q:
Y+ . L/3 Y,
l .  19  r . 26  1 .41
I
2
J
8
2
A
4
t 6
5
J Z
o = 0 =  5
t t = 9 = 1 0
o = 9 = 1 5
a = 9 = 2 0
a = g = 2 5
o = 9 = 5 0
4.2
8.5
12.9
17.4
2 r .9
45.7
4.0
8 . 1
r2.3
16 .5
20.9
44.2
3.6
I  . . )
l l . l
1 5 . 1
19 .1
41.5
2.6
5.3
8 .1
l l . l
r4.3
J J . J
1 .3
2.7
4.2
5.9
7.7
20.0
0.6
1.4
2.2
3.0
4.0
1 1 . 1
0.3
0.7
1 . 1
1 . 5
2.0
5.9
0.2
0.3
0.5
0.8
1 .0
_r..0
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which because ofthe first-order character of
the reactions can be written as:
100-n^o. F 
=(l)tr ta (7)
100 - a llmax
Again, to simplifu the calculations that
follow a new variable p is introduced:
P = (t/z)tttw,
rearrangement of equation 7 then gives
Ilmax =
r00 (8)
Fig.3. Theoretically calculated maximal and mini-
mal coagulation factor levels as a function of time.
'(S*).'
From equation 8 table II can be calcu-
lated, again 'stable' anticoagulation is as-
sumed.
From table II similar conclusions can be
drawn as from table I. Tables I and II can be
combined into figure 3.
When we assume that for vitamin K-
dependent coagulation factors the lowest tol-
erable level is 4o/o and the highest tolerable
level is 40o/o, it can be seen from figure 3 that
at a reasonable coagulation factor level of
100/o for a given coagulation factor the lower
limit can be reached within 1.5 half-time val-
ues and the upper limit within 2.6 half-time
TableII. n-* values as a function ofo, p and (t/ty)
60
l a n
4 " "
I
-:
d 2 0
al
c
.9 ro
o
=
o6
o ^
O U
0 1 2 3
Time/hatf-tife time +
L/ty,i
p:
Vt
0.84
V3
0.79
V2
0.7 |
I
0 .50
z
0.25
J
0 .12
4 5
0.06 0.03
o = F =  5
o - p =  l 0
o = B = 1 5
a = F = 2 0
a = 9 = 2 5
s = F = 5 0
46.7 63.7
64.9 78.7
74.6 85.5
80.6 89.3
84.7 91.7
94.3 97.r
5.9
l l .7
t7 .4
22.9
28.4
54.3
6.2
I  z - J
18 .3
24.0
29.7
55.9
6.9
13 .5
19.9
26.0
3r.9
58.5
9.s
r8.2
26.1
J J . J
40.0
66.7
t7.4
30.8
41.4
50.0
57.1
80.0
30.4
48.  I
59.5
67.6
73.5
89.3
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yalues of the respective coagulation factor.
These calculations clearly show that if the
control interval is more than twice the half-
life time of a given coagulation factor, the
patient may have been in a dangerous zone
even if perfectly stable anticoagulation has
been observed (u, = P).
Having in mind the halflife times of the
vitamin K-dependent coagulation factors
lvan der Meer et al., 19681 the following con-
clusions are justif,red:
(l) The time course of factor VII can
never be used for the control oforal anticoag-
ulation therapy even if the control is as fre-
quent as once per 24 h.
(2) In all cases where the control fre-
quency is once weekly or less, the only factor
that can be followed with some accuracy is
factor IL
(3) Factor IX is the factor of choice in
crucial situations when control is carried out
daily.
(4) Factor X is the factor ofchoice in sit-
uations when the control has to be carried out
2-3 times weekly.
Of course the theoretical lines o-nmin-p
and o-n-u*-p in figure 2 represent extreme
situations and in most practical situations the
coagulation factor levels during the time
lapse t will lie within the theoretical envelope
o-n-in-$-n-u* scattered around the line o-B.
At the moment statistical experiments are
carried out to test the theoretical model in-
troduced above. These statistical experi-
ments will provide knowledge about the scat-
tering ofthe coagulation factor levels around
the line o-B during the time lapse t. In other
words, the statistical experiments will give us
a realistic picture ofthe fluctuations in coag-
ulation factor level during the periods be-
tween successive controls of anticoagulation
theranv.
References
Aiyappa, P.A.: Involvement of factor VII in intrinsic
coagulation pathway: synthetic substrate assay for
coagulation factor activities in plasma. Thromb.
Haemostasis 46: 350 (1981a).
Aiyappa, P.A.: Chromogenic substrate spectropho-
tometric assays for the measurement of clotting
function. Ann. N.Y. Acad. Sci. 370: 812-821
(1 98 l  b).
Altman, R.; Hemker, H.C.: Contact activation in the
extrinsic blood clotting system. Thromb. Diath.
haemorrh. 18: 525-531 (1967).
Awisati, G.; Cate, J.W. ten; Wijk, E.M. van; Kahl6,
L.H.; Mariani. G.: Evaluation of a new chromo-
genic assay for factor VII and its application in
patients on oral anticoagulant treatment. Br. J.
Haemat. 45: 343-352 (1980).
Bertina, R.M.; Alderkamp, G.J.H.; Nooy, E. de: A
variant of factor X that is defective only in extrin-
sic coagulation. Thromb. Haemostasis 46.' 88
(1  98  1) .
Jesty, J.: The inhibition ofactivated bovine coagula-
tion factors X and VII by antithrombin III. Archs
Biochem. Biophys. 185: 165-173 (1978).
Jesty, J.; Silverberg, S.A.: Kinetics of the tissue factor-
dependent activation ofcoagulation factors IX and
X in bovine plasma system. J. biol. Chem. 254;
12337-12345 (19'19).
Josso, F.; Prou-Wartelle, O.: Interaction of tissue fac-
tor and factor VII at the earliest phase of coagula-
tion. Thromb. Diath. haemorrh. 17: suppl.,
pp.35aa 0965).
Hemker, H.C.; Muller, A.D.; Gonggrijp, R.: The esti-
mation of activated human blood coagulation fac-
tor VII. J. mol Med. 1: 127-134 (1976).
Kisiel, W.; Fujikawa, K.; Davie, E.W.: Activation of
bovine factor VII (proconvertin) by factor XII"
(activated Hageman factor). Biochemistry 16:
41894149 (1977).
Meer, J. van der; Hemker, H.C.; Loeliger, E.A.: Phar-
macological aspects of vitamin K1. A clinical and
experimental study in man. Thromb. Diath. hae-
morrh. 19; 1-95 (1968).
Morrison-Silverberg, S.A.; Jesty, J.: The role of
activated factor X in the control of bovine coagu-
lation factor VII. J. biol. Chem. 256: 1625-1630
fl  98 1).
Osterud, B.; Miller-Andersson, M.; Abildgaard, U.;
Prvdz. H.: The effect of anti-thrombin III on the
208 van Dam-Mieras/Hemker
activity of coagulation factors VII, IX and X.
Thromb. Haemostasis 35: 295-304 (1976).
Osterud, B.; Rappaport, S.I.: Activation of factor IX
by the reaction product oftissue factor and factor
VII: additional pathway for initiating blood coagu-
lation. Proc. natn. Acad. Sci. USA 74:5260-5264
(r977).
Osterud, B.; Rappaport, S.I.: Activation of l25l-factor
IX and l2sl-factor X: effect oftissue factor and fac-
tor VII, factor Xu and thrombin. Scand. J. Haema-
tol. 24: 213-226 (1980).
Poller, L.; Thomson, J.M.; Bodzenta, A.; Easton,
A.C.; Latallo, Z.S.; Chmielewska, J.: An assess-
ment of an amidolytic assay for factor VII in the
laboratory control of oral anticoagulants. Bi. J.
Haemat. 49: 49-75 (1981).
Radcliffe, R.; Bagdasarian, A.; Colman, R.; Nemer-
son, Y.: Activation of bovine factor VII by Hage-
man factor fragments. Blood 50: 6ll-617 (1977).
Radcliffe, R.; Nemerson, Y.: Activation and control of
factor VII by activated factor X and thrombin. J.
biol. Chem. 250:388-395 (1975).
Radcliffe, R.; Nemerson, Y.: Mechanism of activation
ofbovine factor VII. Products ofcleavage by factor
X". J. biol. Chem. 251: 47974802 (1976).
Seligsohn, U.; Kasper, C.K.; Osterud, B.; Rappaport,
S.I.: Activated factor VII: presence in factor IX
concentrates and persistence in the circulation af-
ter infusion. Blood 5.?; 828-837 (1979a'1.
Seligsohn, U.; Osterud, B.; Brown, S.F.; Griflin, J.H.;
Rapaport, S.I.: Activation of human factor VII in
plasma and in purifred systems. Roles of activated
factor IX. kallikrein. and activated factor XII. J.
clin. Invest. 64: 1056-1065 (1979b).
Seligsohn, U.; Osterud, B.; Griffrn, J.H.; Rapaport,
S.I.: Evidence for the participation of both acti-
vated factor XII and activated factor IX in cold-
promoted activation of factor VII. Thromb. Res.
1-3: 1049-1056 (1978a).
Seligsohn, U.; Osterud, B.; Rapaport, S.I.: Coupled
amidolytic assay for factor VII: its use with a clot-
ting assay to determine the activity state offactor
VII. Blood 52:978-988 (1978b).
7,a:ugg, H: Thromboplastic activity of human arterial
walls and its interaction with the plasmatic coagu-
lation system. J. clin. Chem. clin. Biochem. 18:
545-549 (1 980).
Zv,M.; Nemerson, Y.: The esterase activity of coag-
ulation factor VII. Evidence for intrinsic activity
of the zymogen. J. biol. Chem. 2JJ: 5703-5707
(l980).
M.C.E. van Dam-Mieras,
Department of Biochemistry,
Limburg University,
Beeldsnijdersdreef 101,
NI-6200 MD Maastricht (The Netherlands)
